Tempest Therapeutics, Inc. — Director's Dealing 2017

Jun 24, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2017-06-21

Reporting Person: GILLIS JONATHAN (Vice President Finance)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-21	Stock Option (right to buy)	$1.46	A	30000	Acquired	2017-06-21	Common Stock (30000)	Direct

Footnotes

F1: The option shall vest as to 25% of the shares on June 14, 2018 and the remaining shares shall vest in equal quarterly installments over 12 quarters, ending on June 14, 2021.